Jade expects to start its JADE101 and JADE301 trials in Q4 2026, and says its $475.7 million can fund operations into Q4 2028. Research spending rose $8.8 million and patient results are still pending, but the cash runway and program progress support a positive reading.
These steps give Jade more chances to test its treatments and reach planned updates. The update also reports promising lab and animal findings for JADE301, but no patient results yet. Research spending rose $8.8 million from the same quarter last year, tempering the positive read.
Follow Jade Biosciences, Inc. (JBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JBIO